Global Primary Hyperoxaluria Drug Market Analysis and Forecast 2025-2031

Summary

According to APO Research, The global Primary Hyperoxaluria Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Primary Hyperoxaluria Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Primary Hyperoxaluria Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Primary Hyperoxaluria Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Primary Hyperoxaluria Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Primary Hyperoxaluria Drug include OxThera AB, Intellia Therapeutics Inc, Dicerna Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc and Allena Pharmaceuticals Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Primary Hyperoxaluria Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Primary Hyperoxaluria Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Primary Hyperoxaluria Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Primary Hyperoxaluria Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Primary Hyperoxaluria Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Primary Hyperoxaluria Drug sales, projected growth trends, production technology, application and end-user industry.

Primary Hyperoxaluria Drug Segment by Company

OxThera AB
Intellia Therapeutics Inc
Dicerna Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Allena Pharmaceuticals Inc

Primary Hyperoxaluria Drug Segment by Type

ALLN-230
ALN-GO1
DCR-PHXC
Others

Primary Hyperoxaluria Drug Segment by Application

Hospital
Clinic
Others

Primary Hyperoxaluria Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Hyperoxaluria Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Primary Hyperoxaluria Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Hyperoxaluria Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Primary Hyperoxaluria Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Primary Hyperoxaluria Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Primary Hyperoxaluria Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Primary Hyperoxaluria Drug Market by Type
1.2.1 Global Primary Hyperoxaluria Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 ALLN-230
1.2.3 ALN-GO1
1.2.4 DCR-PHXC
1.2.5 Others
1.3 Primary Hyperoxaluria Drug Market by Application
1.3.1 Global Primary Hyperoxaluria Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Primary Hyperoxaluria Drug Market Dynamics
2.1 Primary Hyperoxaluria Drug Industry Trends
2.2 Primary Hyperoxaluria Drug Industry Drivers
2.3 Primary Hyperoxaluria Drug Industry Opportunities and Challenges
2.4 Primary Hyperoxaluria Drug Industry Restraints
3 Global Market Growth Prospects
3.1 Global Primary Hyperoxaluria Drug Revenue Estimates and Forecasts (2020-2031)
3.2 Global Primary Hyperoxaluria Drug Revenue by Region
3.2.1 Global Primary Hyperoxaluria Drug Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Primary Hyperoxaluria Drug Revenue by Region (2020-2025)
3.2.3 Global Primary Hyperoxaluria Drug Revenue by Region (2026-2031)
3.2.4 Global Primary Hyperoxaluria Drug Revenue Market Share by Region (2020-2031)
3.3 Global Primary Hyperoxaluria Drug Sales Estimates and Forecasts 2020-2031
3.4 Global Primary Hyperoxaluria Drug Sales by Region
3.4.1 Global Primary Hyperoxaluria Drug Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Primary Hyperoxaluria Drug Sales by Region (2020-2025)
3.4.3 Global Primary Hyperoxaluria Drug Sales by Region (2026-2031)
3.4.4 Global Primary Hyperoxaluria Drug Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Primary Hyperoxaluria Drug Revenue by Manufacturers
4.1.1 Global Primary Hyperoxaluria Drug Revenue by Manufacturers (2020-2025)
4.1.2 Global Primary Hyperoxaluria Drug Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Primary Hyperoxaluria Drug Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Primary Hyperoxaluria Drug Sales by Manufacturers
4.2.1 Global Primary Hyperoxaluria Drug Sales by Manufacturers (2020-2025)
4.2.2 Global Primary Hyperoxaluria Drug Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Primary Hyperoxaluria Drug Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Primary Hyperoxaluria Drug Sales Price by Manufacturers (2020-2025)
4.4 Global Primary Hyperoxaluria Drug Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Primary Hyperoxaluria Drug Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Primary Hyperoxaluria Drug Manufacturers, Product Type & Application
4.7 Global Primary Hyperoxaluria Drug Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Primary Hyperoxaluria Drug Market CR5 and HHI
4.8.2 2024 Primary Hyperoxaluria Drug Tier 1, Tier 2, and Tier 3
5 Primary Hyperoxaluria Drug Market by Type
5.1 Global Primary Hyperoxaluria Drug Revenue by Type
5.1.1 Global Primary Hyperoxaluria Drug Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Primary Hyperoxaluria Drug Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Primary Hyperoxaluria Drug Revenue Market Share by Type (2020-2031)
5.2 Global Primary Hyperoxaluria Drug Sales by Type
5.2.1 Global Primary Hyperoxaluria Drug Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Primary Hyperoxaluria Drug Sales by Type (2020-2031) & (W Units)
5.2.3 Global Primary Hyperoxaluria Drug Sales Market Share by Type (2020-2031)
5.3 Global Primary Hyperoxaluria Drug Price by Type
6 Primary Hyperoxaluria Drug Market by Application
6.1 Global Primary Hyperoxaluria Drug Revenue by Application
6.1.1 Global Primary Hyperoxaluria Drug Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Primary Hyperoxaluria Drug Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Primary Hyperoxaluria Drug Revenue Market Share by Application (2020-2031)
6.2 Global Primary Hyperoxaluria Drug Sales by Application
6.2.1 Global Primary Hyperoxaluria Drug Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Primary Hyperoxaluria Drug Sales by Application (2020-2031) & (W Units)
6.2.3 Global Primary Hyperoxaluria Drug Sales Market Share by Application (2020-2031)
6.3 Global Primary Hyperoxaluria Drug Price by Application
7 Company Profiles
7.1 OxThera AB
7.1.1 OxThera AB Comapny Information
7.1.2 OxThera AB Business Overview
7.1.3 OxThera AB Primary Hyperoxaluria Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 OxThera AB Primary Hyperoxaluria Drug Product Portfolio
7.1.5 OxThera AB Recent Developments
7.2 Intellia Therapeutics Inc
7.2.1 Intellia Therapeutics Inc Comapny Information
7.2.2 Intellia Therapeutics Inc Business Overview
7.2.3 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Product Portfolio
7.2.5 Intellia Therapeutics Inc Recent Developments
7.3 Dicerna Pharmaceuticals Inc
7.3.1 Dicerna Pharmaceuticals Inc Comapny Information
7.3.2 Dicerna Pharmaceuticals Inc Business Overview
7.3.3 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
7.3.5 Dicerna Pharmaceuticals Inc Recent Developments
7.4 Alnylam Pharmaceuticals Inc
7.4.1 Alnylam Pharmaceuticals Inc Comapny Information
7.4.2 Alnylam Pharmaceuticals Inc Business Overview
7.4.3 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
7.4.5 Alnylam Pharmaceuticals Inc Recent Developments
7.5 Allena Pharmaceuticals Inc
7.5.1 Allena Pharmaceuticals Inc Comapny Information
7.5.2 Allena Pharmaceuticals Inc Business Overview
7.5.3 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Product Portfolio
7.5.5 Allena Pharmaceuticals Inc Recent Developments
8 North America
8.1 North America Primary Hyperoxaluria Drug Market Size by Type
8.1.1 North America Primary Hyperoxaluria Drug Revenue by Type (2020-2031)
8.1.2 North America Primary Hyperoxaluria Drug Sales by Type (2020-2031)
8.1.3 North America Primary Hyperoxaluria Drug Price by Type (2020-2031)
8.2 North America Primary Hyperoxaluria Drug Market Size by Application
8.2.1 North America Primary Hyperoxaluria Drug Revenue by Application (2020-2031)
8.2.2 North America Primary Hyperoxaluria Drug Sales by Application (2020-2031)
8.2.3 North America Primary Hyperoxaluria Drug Price by Application (2020-2031)
8.3 North America Primary Hyperoxaluria Drug Market Size by Country
8.3.1 North America Primary Hyperoxaluria Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Primary Hyperoxaluria Drug Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Primary Hyperoxaluria Drug Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe Primary Hyperoxaluria Drug Market Size by Type
9.1.1 Europe Primary Hyperoxaluria Drug Revenue by Type (2020-2031)
9.1.2 Europe Primary Hyperoxaluria Drug Sales by Type (2020-2031)
9.1.3 Europe Primary Hyperoxaluria Drug Price by Type (2020-2031)
9.2 Europe Primary Hyperoxaluria Drug Market Size by Application
9.2.1 Europe Primary Hyperoxaluria Drug Revenue by Application (2020-2031)
9.2.2 Europe Primary Hyperoxaluria Drug Sales by Application (2020-2031)
9.2.3 Europe Primary Hyperoxaluria Drug Price by Application (2020-2031)
9.3 Europe Primary Hyperoxaluria Drug Market Size by Country
9.3.1 Europe Primary Hyperoxaluria Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Primary Hyperoxaluria Drug Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Primary Hyperoxaluria Drug Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China Primary Hyperoxaluria Drug Market Size by Type
10.1.1 China Primary Hyperoxaluria Drug Revenue by Type (2020-2031)
10.1.2 China Primary Hyperoxaluria Drug Sales by Type (2020-2031)
10.1.3 China Primary Hyperoxaluria Drug Price by Type (2020-2031)
10.2 China Primary Hyperoxaluria Drug Market Size by Application
10.2.1 China Primary Hyperoxaluria Drug Revenue by Application (2020-2031)
10.2.2 China Primary Hyperoxaluria Drug Sales by Application (2020-2031)
10.2.3 China Primary Hyperoxaluria Drug Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Primary Hyperoxaluria Drug Market Size by Type
11.1.1 Asia Primary Hyperoxaluria Drug Revenue by Type (2020-2031)
11.1.2 Asia Primary Hyperoxaluria Drug Sales by Type (2020-2031)
11.1.3 Asia Primary Hyperoxaluria Drug Price by Type (2020-2031)
11.2 Asia Primary Hyperoxaluria Drug Market Size by Application
11.2.1 Asia Primary Hyperoxaluria Drug Revenue by Application (2020-2031)
11.2.2 Asia Primary Hyperoxaluria Drug Sales by Application (2020-2031)
11.2.3 Asia Primary Hyperoxaluria Drug Price by Application (2020-2031)
11.3 Asia Primary Hyperoxaluria Drug Market Size by Country
11.3.1 Asia Primary Hyperoxaluria Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Primary Hyperoxaluria Drug Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Primary Hyperoxaluria Drug Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Primary Hyperoxaluria Drug Market Size by Type
12.1.1 SAMEA Primary Hyperoxaluria Drug Revenue by Type (2020-2031)
12.1.2 SAMEA Primary Hyperoxaluria Drug Sales by Type (2020-2031)
12.1.3 SAMEA Primary Hyperoxaluria Drug Price by Type (2020-2031)
12.2 SAMEA Primary Hyperoxaluria Drug Market Size by Application
12.2.1 SAMEA Primary Hyperoxaluria Drug Revenue by Application (2020-2031)
12.2.2 SAMEA Primary Hyperoxaluria Drug Sales by Application (2020-2031)
12.2.3 SAMEA Primary Hyperoxaluria Drug Price by Application (2020-2031)
12.3 SAMEA Primary Hyperoxaluria Drug Market Size by Country
12.3.1 SAMEA Primary Hyperoxaluria Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Primary Hyperoxaluria Drug Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Primary Hyperoxaluria Drug Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Primary Hyperoxaluria Drug Value Chain Analysis
13.1.1 Primary Hyperoxaluria Drug Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Primary Hyperoxaluria Drug Production Mode & Process
13.2 Primary Hyperoxaluria Drug Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Primary Hyperoxaluria Drug Distributors
13.2.3 Primary Hyperoxaluria Drug Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings